Using Molecular Markers to Guide Therapy of Metastatic Colorectal Cancer

about

Using Molecular Markers to Guide Therapy of Metastatic Colorectal Cancer

Item

http://www.wikidata.org/entity/Q36341759

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh

2013年學術文章

@zh-hant

name

Using Molecular Markers to Guide Therapy of Metastatic Colorectal Cancer

@ast

Using Molecular Markers to Guide Therapy of Metastatic Colorectal Cancer

@en

type

Item

label

Using Molecular Markers to Guide Therapy of Metastatic Colorectal Cancer

@ast

Using Molecular Markers to Guide Therapy of Metastatic Colorectal Cancer

@en

prefLabel

Using Molecular Markers to Guide Therapy of Metastatic Colorectal Cancer

@ast

Using Molecular Markers to Guide Therapy of Metastatic Colorectal Cancer

@en

P1476

Using Molecular Markers to Guide Therapy of Metastatic Colorectal Cancer

@en

P2093

Autumn McRee

http://www.w3.org/2001/XMLSchema#string

Bert H O'Neil

http://www.w3.org/2001/XMLSchema#string

P2860

Prognostic Role of PIK3CA Mutation in Colorectal Cancer: Cohort Study and Literature Review

The PI3K pathway as drug target in human cancer

Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer.

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies.

Influence of GSTP1 I105V polymorphism on cumulative neuropathy and outcome of FOLFOX-4 treatment in Asian patients with colorectal carcinoma.

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.

Cancer statistics, 2012

5-fluorouracil: mechanisms of action and clinical strategies

P304

21-29

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.13032/TJOP.2052-5931.100056

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2013-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26640695

http://www.w3.org/2001/XMLSchema#string

P921

colorectal cancer

P932

4667749

http://www.w3.org/2001/XMLSchema#string